Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. more
Time Frame | VIR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.01% | -2.06% | -0.55% |
1-Month Return | 4.55% | -1.92% | 2.72% |
3-Month Return | -5.77% | -10.4% | 7.66% |
6-Month Return | -17.88% | -4.6% | 10.15% |
1-Year Return | -24.38% | 4.06% | 27.53% |
3-Year Return | -85.63% | 1.94% | 32.31% |
5-Year Return | -40.63% | 36.48% | 89.2% |
10-Year Return | -47.57% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 711.00K | 76.37M | 1.09B | 1.58B | 86.18M | [{"date":"2019-12-31","value":0.04,"profit":true},{"date":"2020-12-31","value":4.83,"profit":true},{"date":"2021-12-31","value":68.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":5.45,"profit":true}] |
Cost of Revenue | 143.07M | 301.58M | 65.86M | 146.32M | 2.77M | [{"date":"2019-12-31","value":47.44,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":21.84,"profit":true},{"date":"2022-12-31","value":48.52,"profit":true},{"date":"2023-12-31","value":0.92,"profit":true}] |
Gross Profit | 711.00K | 76.37M | 1.02B | 1.43B | 83.42M | [{"date":"2019-12-31","value":0.05,"profit":true},{"date":"2020-12-31","value":5.32,"profit":true},{"date":"2021-12-31","value":71.21,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":5.82,"profit":true}] |
Gross Margin | 100.00% | 100.00% | 93.94% | 90.74% | 96.79% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.94,"profit":true},{"date":"2022-12-31","value":90.74,"profit":true},{"date":"2023-12-31","value":96.79,"profit":true}] |
Operating Expenses | 178.69M | 373.35M | 600.45M | 601.09M | 767.72M | [{"date":"2019-12-31","value":23.28,"profit":true},{"date":"2020-12-31","value":48.63,"profit":true},{"date":"2021-12-31","value":78.21,"profit":true},{"date":"2022-12-31","value":78.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (177.98M) | (296.98M) | 276.89M | 833.07M | (684.30M) | [{"date":"2019-12-31","value":-21.36,"profit":false},{"date":"2020-12-31","value":-35.65,"profit":false},{"date":"2021-12-31","value":33.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-82.14,"profit":false}] |
Total Non-Operating Income/Expense | 11.96M | 299.52M | 129.49M | (50.70M) | 138.54M | [{"date":"2019-12-31","value":3.99,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.23,"profit":true},{"date":"2022-12-31","value":-16.93,"profit":false},{"date":"2023-12-31","value":46.25,"profit":true}] |
Pre-Tax Income | (174.53M) | (298.61M) | 549.80M | 754.28M | (628.19M) | [{"date":"2019-12-31","value":-23.14,"profit":false},{"date":"2020-12-31","value":-39.59,"profit":false},{"date":"2021-12-31","value":72.89,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-83.28,"profit":false}] |
Income Taxes | 154.00K | (54.00K) | 21.22M | 238.44M | (13.08M) | [{"date":"2019-12-31","value":0.06,"profit":true},{"date":"2020-12-31","value":-0.02,"profit":false},{"date":"2021-12-31","value":8.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-5.48,"profit":false}] |
Income After Taxes | (174.68M) | (298.56M) | 528.58M | 515.84M | (615.12M) | [{"date":"2019-12-31","value":-33.05,"profit":false},{"date":"2020-12-31","value":-56.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.59,"profit":true},{"date":"2023-12-31","value":-116.37,"profit":false}] |
Income From Continuous Operations | (174.68M) | (298.67M) | 528.58M | 515.84M | (600.75M) | [{"date":"2019-12-31","value":-33.05,"profit":false},{"date":"2020-12-31","value":-56.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.59,"profit":true},{"date":"2023-12-31","value":-113.65,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (174.68M) | (298.67M) | 528.58M | 515.84M | (615.06M) | [{"date":"2019-12-31","value":-33.05,"profit":false},{"date":"2020-12-31","value":-56.5,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.59,"profit":true},{"date":"2023-12-31","value":-116.36,"profit":false}] |
EPS (Diluted) | (6.00) | (2.48) | 3.88 | 3.81 | (4.59) | [{"date":"2019-12-31","value":-154.51,"profit":false},{"date":"2020-12-31","value":-63.92,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.2,"profit":true},{"date":"2023-12-31","value":-118.3,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
VIR | |
---|---|
Cash Ratio | 8.52 |
Current Ratio | 8.94 |
Quick Ratio | 8.98 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
VIR | |
---|---|
ROA (LTM) | -19.41% |
ROE (LTM) | -36.58% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
VIR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.17 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.83 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
VIR | |
---|---|
Trailing PE | NM |
Forward PE | 4.36 |
P/S (TTM) | 13.24 |
P/B | 0.84 |
Price/FCF | NM |
EV/R | 3.86 |
EV/Ebitda | 0.90 |
Vir Biotechnology Inc (VIR) share price today is $7.156
Yes, Indians can buy shares of Vir Biotechnology Inc (VIR) on Vested. To buy Vir Biotechnology Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VIR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Vir Biotechnology Inc (VIR) via the Vested app. You can start investing in Vir Biotechnology Inc (VIR) with a minimum investment of $1.
You can invest in shares of Vir Biotechnology Inc (VIR) via Vested in three simple steps:
The 52-week high price of Vir Biotechnology Inc (VIR) is $13.09. The 52-week low price of Vir Biotechnology Inc (VIR) is $6.56.
The price-to-earnings (P/E) ratio of Vir Biotechnology Inc (VIR) is
The price-to-book (P/B) ratio of Vir Biotechnology Inc (VIR) is 0.84
The dividend yield of Vir Biotechnology Inc (VIR) is 0.00%
The market capitalization of Vir Biotechnology Inc (VIR) is $1.04B
The stock symbol (or ticker) of Vir Biotechnology Inc is VIR